Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | HSPA5 | P11021 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833037 | 0.82 | CYP2C19 (0.70) | CYP2C19CYP2C9HIF1ASMN1; SMN2TP53 | |
| SCHEMBL9768525 | 0.81 | CYP2C19 (0.68) | CYP2C19CYP2C9HIF1ASMN1; SMN2TP53 | |
| SCHEMBL10488673 | 0.79 | SMN1; SMN2 (0.65) | CYP2C19CYP2C9HIF1ASMN1; SMN2TP53 | |
| SCHEMBL70212 | 0.78 | HIF1A (0.63) | CYP2C19CYP2C9HIF1ASMN1; SMN2TP53 | |
| SCHEMBL11883439 | 0.78 | SMN1; SMN2 (0.62) | CYP2C19CYP2C9HIF1ASMN1; SMN2TP53 | |
| SCHEMBL27962109 | 0.77 | SMN1; SMN2 (0.62) | CYP2C19CYP2C9HIF1ASMN1; SMN2TP53 | |
| SCHEMBL30337501 | 0.76 | CYP2C19 (0.62) | CYP2C19CYP2C9HIF1ASMN1; SMN2TP53 | |
| SCHEMBL3039574 | 0.75 | SMN1; SMN2 (0.59) | CYP2C19CYP2C9HIF1ASMN1; SMN2TP53 | |
| SCHEMBL30337249 | 0.73 | CYP2C19 (0.58) | CYP2C19CYP2C9HIF1ASMN1; SMN2TP53 | |
| SCHEMBL10814873 | 0.73 | CYP2C19 (0.61) | CYP2C19CYP2C9HIF1ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9504729-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504729-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-02-04 | — | — | US | disclosed |
| US-9186365-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-17 | — | — | US | disclosed |
| US-9186365-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-17 | — | — | US | disclosed |
| US-8779202-B2 | Compositions and methods for the treatment of giardiasis | GEORGETOWN UNIVERSITY (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779202-B2 | Compositions and methods for the treatment of giardiasis | GEORGETOWN UNIVERSITY (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120283267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GIARDIASIS | GEORGETOWN UNIVERSITY (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GIARDIASIS | GEORGETOWN UNIVERSITY (US) | 2012-11-08 | — | — | US | disclosed |
| EP-2479203-A1 | AROMATIC POLYESTER | Muroran Institute of Technology (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120172570-A1 | AROMATIC POLYESTER | NITTA CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| US-8129493-B2 | Aromatic polyester | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2011-09-15 | — | — | US | disclosed |
| WO-2011068987-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GIARDIASIS | GEORGETOWN UNIVERSITY (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110092662-A1 | AROMATIC POLYESTER | NITTA CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2011014825-A2 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | F12, PHAX, WDR82 | CYP2C19 3009/4885CYP2C9 2591/4885HIF1A 1324/4885 |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | CYP2C19 4841/4885CYP2C9 4864/4885HIF1A 85/4885 |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | CYP2C19 4841/4885CYP2C9 4864/4885HIF1A 85/4885 |
| US-20120283267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GIARDIASIS | FABP2, SI, GGH | CYP2C19 1596/4885CYP2C9 2195/4885HIF1A 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.